Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer

The Journal of Urology
Juan PalouHumberto Villavicencio

Abstract

In this phase I study we determined the pharmacokinetic and toxicity profiles of a single intravesical instillation of gemcitabine administered immediately after complete transurethral resection (TUR) plus multiple random biopsies. Ten patients with superficial bladder cancer clinically staged as Ta/T1 with no carcinoma in situ were included. A single dose of gemcitabine was administered intra-vesically immediately after TUR plus 6 random biopsies. Five patients received 1,500 mg and 5 received 2,000 mg diluted in 100 ml saline. Retention time in the bladder was 60 minutes. Concentrations of gemcitabine and dFdU (2',2'-difluoro-2'-deoxyuridine) were determined by high pressure liquid chromatography assay. Treatment was clinically well tolerated in all patients. Two patients in the 1,500 mg group had minimal hipogastric discomfort and 1 in the 2,000 mg group had grade 1 bladder spasms. There was no remarkable systemic toxicity on hematology or biochemistry at any dose level on day 12 or 30. One patient per dose level showed tumor recurrence on 3-month repeat cystourethroscopy. Mean maximum gemcitabine concentration was 1.8 microg/ml and the mean last AUC was 158 microg/ml*minute. There was large interpatient variability but no s...Continue Reading

References

Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Nov 18, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M StadlerF A Dorr
Dec 13, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J MooreN Murray
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V LorussoM De Lena
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A B SandlerL H Einhorn
Jul 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P VenookM J Ratain
Aug 23, 2000·The Journal of Urology·F Millán-RodríguezJ Vicente-Rodríguez
Jul 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S FogliM Del Tacca
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido DalbagniDean Bajorin
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Menachem LauferMerrill J Egorin
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph GibbonsUNKNOWN National Cancer Institute Organ Dysfunction Working Group

❮ Previous
Next ❯

Citations

Feb 24, 2006·Urologia Internationalis·Mauro GacciUNKNOWN TUR (Toscana Urologia) Group
Jun 14, 2008·Expert Opinion on Investigational Drugs·J Alfred Witjes, Prasad S Kolli
Oct 20, 2015·Expert Opinion on Drug Delivery·Pradeep TyagiNaoki Yoshimura
Jul 2, 2010·BJU International·Paolo GonteroAlessandro Tizzani
Jun 24, 2006·European Urology·Juan Pablo Burgués Gasión, Juan Fernando Jiménez Cruz
Jul 6, 2014·Developmental Biology·Weilun SunEgbert Oosterwijk
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido DalbagniDean Bajorin
Sep 23, 2010·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Susan MannersPaul de Souza
Aug 15, 2006·Current Opinion in Urology·Kees Hendricksen, J Alfred Witjes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.